Patents by Inventor Mark A. Mulvihill

Mark A. Mulvihill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190276446
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Patent number: 10301297
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 28, 2019
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Publication number: 20180222897
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Patent number: 9951056
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 24, 2018
    Assignee: BEIJING INNOCARE PHARMA TECH CO., LTD.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Publication number: 20160237075
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: September 29, 2014
    Publication date: August 18, 2016
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Patent number: 7662844
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: February 16, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Vanessa Smith, Anthony Nigro, Mark Mulvihill, Cara Cesario, Patricia Anne Beck, Arlindo L. Castelhano
  • Publication number: 20080227788
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: October 14, 2004
    Publication date: September 18, 2008
    Inventors: Patricia Beck, Cara Cesario, Matthew Cox, Han-Qing Dong, Kenneth Foreman, Mark Mulvihill, Anthony Nigro, Lydia Saroglou, Arno Steinig, Yingchuan Sun, Qinghua Weng, Douglas Werner, Robin Wilkes, Jonathan Williams
  • Publication number: 20080014200
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The IGF1R inhibitor is represented by Formula I: wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein.
    Type: Application
    Filed: April 13, 2007
    Publication date: January 17, 2008
    Inventors: Lee Arnold, Qun-Sheng Ji, Mark Mulvihill
  • Publication number: 20070208053
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X5, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.
    Type: Application
    Filed: January 18, 2007
    Publication date: September 6, 2007
    Inventors: Lee Arnold, Xin Chen, Hanqing Dong, Andrew Garton, Mark Mulvihill, Colin Sambrook Smith, Gerard Thomas, Thomas Krulle, Jing Wang
  • Publication number: 20070149521
    Abstract: Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: December 4, 2006
    Publication date: June 28, 2007
    Inventors: Andrew Crew, Han-Qing Dong, Mark Mulvihill, Douglas Werner, Mridula Kadalbajoo, Radoslaw Laufer
  • Publication number: 20070129364
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 7, 2007
    Inventors: Han-Qing Dong, Kenneth Foreman, An-Hu Li, Mark Mulvihill, Bijoy Panicker, Arno Steinig, Kathryn Stolz, Qinghua Weng, Meizhong Jin, Brian Volk, Jing Wang, Ti Wang, James Beard
  • Publication number: 20070112005
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Application
    Filed: November 15, 2006
    Publication date: May 17, 2007
    Inventors: Xin Chen, Heather Coate, Andrew Crew, Han-Qing Dong, Ayako Honda, Mark Mulvihill, Paula Tavares, Jing Wang, Douglas Werner, Kristen Mulvihill, Kam Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James Beard
  • Publication number: 20070032512
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: August 3, 2006
    Publication date: February 8, 2007
    Inventors: Qun-Sheng Ji, Mark Mulvihill, Arno Steinig, Qinghua Weng
  • Publication number: 20060235031
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 19, 2006
    Inventors: Lee Arnold, Heather Coate, Andrew Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Mark Mulvihill, Anthony Nigro, Bijoy Panicker, Arno Steinig, Qingua Weng, Douglas Werner, Michael Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Publication number: 20060084654
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: October 14, 2004
    Publication date: April 20, 2006
    Inventors: Patricia Beck, Cara Cesario, Matthew Cox, Han-Qing Dong, Kenneth Foreman, Mark Mulvihill, Anthony Nigro, Lydia Saroglou, Arno Steinig, Yingchuan Sun, Qinghua Weng, Douglas Werner, Robin Wilkes, Jonathan Williams
  • Publication number: 20060019957
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: July 20, 2005
    Publication date: January 26, 2006
    Inventors: Andrew Crew, Mark Mulvihill, Douglas Werner
  • Publication number: 20060009645
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
    Type: Application
    Filed: July 12, 2004
    Publication date: January 12, 2006
    Inventors: Vanessa Smith, Anthony Nigro, Mark Mulvihill, Cara Cesario, Patricia Beck, Arlindo Castelhano
  • Patent number: 5492642
    Abstract: An aqueous top of rail lubricant comprises a synthetic lubricant, a synthetic thickener, propylene glycol and ethanol. The lubricating composition is consumed in 5 to 15 minutes in the heat generated by a passing train. The lubricant is environmentally innocuous.
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: February 20, 1996
    Assignee: Texaco Inc.
    Inventors: Mark A. Mulvihill, Arnold C. Witte, Jr.
  • Patent number: 5415896
    Abstract: Railroad wheel flange lubricating is carried out with a lubricating composition which is particularly useful in a locomotive-mounted applicator. The water base lubricant comprises a compatible blend of two polyoxyalkylene glycols, one a synthetic lubricant and the other a synthetic thickener. The lubricating composition is persistent and environmentally innocuous.
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: May 16, 1995
    Assignee: Texaco Inc.
    Inventors: Mark A. Mulvihill, Arnold C. Witte, Frank K. Botz
  • Patent number: 4648985
    Abstract: Lubricant additives are provided which provide extreme pressure properties without the need for lead compositions. The extreme pressure additive system includes a dithio carbamate substituent, an organic copper substituent; and an phosphate substituent which are provided in a three component or two component system.
    Type: Grant
    Filed: July 7, 1986
    Date of Patent: March 10, 1987
    Assignee: The Whitmore Manufacturing Company
    Inventors: Paul W. Thorsell, Mark A. Mulvihill